



		CDR2	FR3
AHM	(SEQ ID NO: 130)	5 0123456	6 7 8 78901234567890123456789012345678
HuSG	I (SEQ ID NO: 131)	SASNRYT	GVPDRITGSGSGTDFTFTISSLQPEDFATYYC
REI	(SEQ ID NO: 132)	-----	GVPSRFSGSAGGTDFTLTISSLQPEDFATYYC
RVLa	(SEQ ID NO: 133)	-----	GVPSRFSGSAGGTDFLTISLQPEDIATYYC
RVLb	(SEQ ID NO: 134)	-----	-----Y-----

  

		CDR3	FR4
AHM	(SEQ ID NO: 130)	9 901234567	10 8901234567
HuSG	I (SEQ ID NO: 131)	QQHYSTPFT	FGSGTKLEIK
REI	(SEQ ID NO: 132)	-----	FGQGTKVEIK
RVLa	(SEQ ID NO: 133)	-----	-----
RVLb	(SEQ ID NO: 134)	-----	-----

On page 62, delete Table 4, and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Table 4

## The amino acid sequence of the H chain V region (1)

	FRI	1	2	3	CDR1	FR2
AHM	(SEQ ID NO: 135)	123456789012345678901234567890	12345	4	67890123456789	
HuSGI	(SEQ ID NO: 136)	QVQLQQSGAELARPGASVKLSCKASGYTFT	PYWMQ		WVKQRPGQGLEWIG	
HG3	(SEQ ID NO: 137)	EVQLVQSGADVKKPGXSVXVSCKASGYTFS			WVRQAPGXGLDWVG	
RVHa	(SEQ ID NO: 138)	QVQLVQSGAEVKKPGASVKVSCKASGYTFN			WVRQAPGQGLEWMG	
RVHb	(SEQ ID NO: 139)	-----T			-----	
RVHc	(SEQ ID NO: 140)	-----T			-----	
RVHd	(SEQ ID NO: 141)	-----T			-----	
RVHe	(SEQ ID NO: 142)	-----T			-----	
RVHf	(SEQ ID NO: 143)	-----T			-----	
RVHg	(SEQ ID NO: 144)	-----T			-----R	
RVhh	(SEQ ID NO: 145)	-----T			-----	
RVhi	(SEQ ID NO: 146)	-----T			-----	
RVHj	(SEQ ID NO: 147)	-----T			-----	
RVhk	(SEQ ID NO: 148)	-----T			-----	
RVhl	(SEQ ID NO: 149)	-----T			-----	
RVhm	(SEQ ID NO: 150)	-----T			-----	
RVhn	(SEQ ID NO: 151)	-----T			-----	
RVho	(SEQ ID NO: 152)	-----T			-----	
RVhp	(SEQ ID NO: 153)	-----T			-----	
RVhq	(SEQ ID NO: 154)	-----T			-----	
RVhr	(SEQ ID NO: 155)	-----T			-----	

Table 5

On page 63, delete Table 5, and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

		CDR2	FR3
		5 6	7 8 9
AHM	(SEQ ID NO: 156)	012A3456789012345	67890123456789012ABC345678901234
HuSGI	(SEQ ID NO: 157)	SIFPGDGDTRYSQKFKG	KATLTADKSSSTAYMQLSILAFEDSAVYYCAR
JH6	(SEQ ID NO: 158)		RVTXTDXSXNTAYMELSSLRSEDTAVYYCAR
RVHa	(SEQ ID NO: 159)		RVTMTRDTSTVYMELSSLRSEDTAVYYCAR
RVHb	(SEQ ID NO: 160)	-----	-----A-----
RVHc	(SEQ ID NO: 161)	-----	K-----A-----
RVhd	(SEQ ID NO: 162)	-----	-----A-K-----
RVhe	(SEQ ID NO: 163)	-----	K----A-K-----
RVhf	(SEQ ID NO: 164)	-----	-A-L-A-----
RVhg	(SEQ ID NO: 165)	-----	-A-L-A---S-A-----
RVhh	(SEQ ID NO: 166)	-----	-----A-----
RVhi	(SEQ ID NO: 167)	-----	K----A---S-A-----
RVhj	(SEQ ID NO: 168)	-----	K----A---S-A-----AF-----
RVhk	(SEQ ID NO: 169)	-----	KA-L-A---S-A-----
RVh1	(SEQ ID NO: 170)	-----	K----A---S==A---Q-----
RVhm	(SEQ ID NO: 171)	-----	K----A---S---A---Q---l-----
RVhn	(SEQ ID NO: 172)	-----	K----A---S---A---Q---l-----S-----
RVho	(SEQ ID NO: 173)	-----	K----A---S---A-----l-----
RVhp	(SEQ ID NO: 174)	-----	K----A---S---A-----S-----
RVhq	(SEQ ID NO: 175)	-----	-----A-----A-----
RVhr	(SEQ ID NO: 176)	-----	-----A-----S-----
			-----A-K-----A-----

On page 64, delete Table 6, and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Table 6

		CDR3	FR4
		10	11
AHM	(SEQ ID NO: 177)	57890ABJK12	34567890123
HuSGI	(SEQ ID NO: 178)	GLRRGGYYFDY	WGQGTTLVSS
JH6	(SEQ ID NO: 179)	-----	WGQGTLTVSS
RVHa	(SEQ ID NO: 180)	-----	-----
RVHb	(SEQ ID NO: 181)	-----	-----
RVHc	(SEQ ID NO: 182)	-----	-----
RVhd	(SEQ ID NO: 183)	-----	-----
RVhe	(SEQ ID NO: 184)	-----	-----
RVhf	(SEQ ID NO: 185)	-----	-----
RVhg	(SEQ ID NO: 186)	-----	-----
RVhh	(SEQ ID NO: 187)	-----	-----
RVhi	(SEQ ID NO: 188)	-----	-----
RVhj	(SEQ ID NO: 189)	-----	-----
RVhk	(SEQ ID NO: 190)	-----	-----
RVh1	(SEQ ID NO: 191)	-----	-----
RVhm	(SEQ ID NO: 192)	-----	-----

PJL  
RVHn (SEQ ID NO: 193) -----  
RVHo (SEQ ID NO: 194) -----  
RVHp (SEQ ID NO: 195) -----  
RVHQ (SEQ ID NO: 196) -----  
RVHr (SEQ ID NO: 197) -----

---

On page 72, delete Table Design of V Region of Natural Humanized Antibody, and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Design of V region of Natural Humanized Antibody

A) L chain	FR1	CDR1	FR2	CDR2
HM1.24 (SEQ ID NO: 130)	12345678901234567890123	45678901234	567890123456789	0123456
HuSG I (SEQ ID NO: 131)	DIVMTQSHKFMSTSVDGRVSITC	KASQDVNTAVA	WYQQKPGQSPKLLY	SASNRYT
REI (SEQ ID NO: 132)	DIQMTQSPSLSASVGDRVTITC		WYQQKPGKAPKLLY	
Primary design (RVLa (SEQ ID NO: 133))	DIQMTQSPSLSASVGDRVTITC		WYQQKPGKAPKLLY	
Secondary design (SEQ ID NO: 133)	-----	-----	-----	-----
<i>B5</i>				
FR3	CDR1	FR2		
HM1.24 (SEQ ID NO: 130)	6 7 8	9	10	
HuSG I (SEQ ID NO: 131)	7890123456789012345678	901234567VA	8901234567	
REI (SEQ ID NO: 132)	GVPDRITGSGGTDFTFTISSVQAEDLALYYC	QQHYSTPFT	FGSGTKLEIK	
Primary design (RVLa (SEQ ID NO: 133))	GVPSRFSGSGGTDFTLTISSLQPEDFATYYC		FGQGTKEIK	
Secondary design (SEQ ID NO: 133)	GVPSRFSGSGGTDFTLTISSLQPEDFATYYC		FGQGTKEIK	
ID NO: 133)	-----	-----	-----	-----

On page 73, delete Table Design of V Region of Natural Humanized Antibody, and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Design of V region of Natural Humanized Antibody

B) H chain	FR1	FR2	CDR1	FR2	CDR2
HM1.24 (SEQ ID NO: 198) HuSG I (SEQ ID NO: 199) HG3 (SEQ ID NO: 200)	1 123456789012345678901234567890 QVQLVQSGAELARPGASVVKLSCSKASGYFT EVQLVQSGADVVKRPGXSVXVSCKASGYTES QVQLVQSGAEVVKRPGASVVKVSKASGYTFN	2 3 4 12345 PYWMQ	3 67890123456789 WVKQRPGQGLEWIG WVRQAPGXGLDWYG WVRQAPGQGLEWMG	5 6 7 012A3456789012345 SIFPGDGDRYSQKEFG	
Primary design (RVHr (SEQ ID NO: 201) Secondary design (2ndRVH) (SEQ ID NO: 202)	-----T -----T	-----T -----T	-----T -----T	-----T -----T	-----T -----T
HM1.24 (SEQ ID NO: 198) HuSG I (SEQ ID NO: 199) HG3 (SEQ ID NO: 200)	FR3 7 67890123456789012ABC345678901234 KATLTADKSSSTAYMQLSILAFEDSAVYYCAR RVTXTDXSXNTAYMELSSLRSEDTAVYYCAR RVTMTRDTSTVYMELSSLRSEDTAVYYCAR	FR3 8 9 10 57890ABJK12 GLRRGGYYFDY	FR2 11 34567890123 WGQQNTTLTVSS WGQQNTTVTSS		
Primary design (RVHr (SEQ ID NO: 201) Secondary design (2ndRVH) (SEQ ID NO: 202)	-----A-K-----A -----I-A-K-----A	-----A-K-----A -----I-A-K-----A	-----A-K-----A -----I-A-K-----A	-----A-K-----A -----I-A-K-----A	-----A-K-----A -----I-A-K-----A

On page 74, delete line 23 and replace this with the following in accordance with  
37 C.F.R. § 1.121. A marked up version showing changes is attached:

*(b)1*  
FR3 of primary design antibody (SEQ ID NO: 203)